Overview

• Researchers at Xi’an Jiaotong-Liverpool University and Nanjing University coassembled medical-grade PLGA with albumin to form supraparticles with exceptional colloidal stability.
• The hybrid nanoparticles achieved drug-loading efficiencies up to 40% by weight for doxorubicin, compared with roughly 11% in existing formulations.
• In vitro and in vivo studies demonstrated effective tumor targeting and delivery with significantly less damage to healthy tissues.
• The nanoparticles remained intact for over six months under laboratory conditions, outperforming most current delivery systems.
• Preliminary scale-up experiments preserved particle quality and the team plans to adapt the platform to carry a wider range of therapeutics.